IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ALBERICI, FEDERICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.197
AS - Asia 3.180
EU - Europa 1.815
SA - Sud America 802
AF - Africa 87
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.100
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.088
SG - Singapore 1.213
CN - Cina 759
BR - Brasile 671
HK - Hong Kong 459
IT - Italia 439
VN - Vietnam 288
UA - Ucraina 236
DE - Germania 234
GB - Regno Unito 184
RU - Federazione Russa 150
FR - Francia 144
TR - Turchia 140
FI - Finlandia 111
IE - Irlanda 80
IN - India 75
PL - Polonia 60
AR - Argentina 56
CA - Canada 54
BD - Bangladesh 43
MX - Messico 36
NL - Olanda 35
IQ - Iraq 34
JP - Giappone 31
ID - Indonesia 26
ZA - Sudafrica 24
AT - Austria 23
SA - Arabia Saudita 20
SE - Svezia 19
DZ - Algeria 18
EC - Ecuador 18
CO - Colombia 17
CZ - Repubblica Ceca 16
EG - Egitto 14
MA - Marocco 14
ES - Italia 13
PY - Paraguay 13
BE - Belgio 10
LT - Lituania 10
UZ - Uzbekistan 10
EU - Europa 9
PK - Pakistan 9
CL - Cile 8
IR - Iran 7
AU - Australia 6
IL - Israele 6
KZ - Kazakistan 6
MY - Malesia 6
PE - Perù 6
PT - Portogallo 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
KE - Kenya 5
KG - Kirghizistan 5
PH - Filippine 5
RO - Romania 5
RS - Serbia 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
DK - Danimarca 4
HU - Ungheria 4
JM - Giamaica 4
JO - Giordania 4
DO - Repubblica Dominicana 3
GY - Guiana 3
LB - Libano 3
LV - Lettonia 3
NP - Nepal 3
VE - Venezuela 3
AM - Armenia 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
EE - Estonia 2
ET - Etiopia 2
HR - Croazia 2
KR - Corea 2
LU - Lussemburgo 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
CG - Congo 1
CI - Costa d'Avorio 1
GE - Georgia 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
KI - Kiribati 1
MD - Moldavia 1
MM - Myanmar 1
Totale 10.094
Salva come PNG Salva come JPEG
Città #
Singapore 596
Hong Kong 458
Ashburn 426
Fairfield 420
San Jose 261
The Dalles 239
Woodbridge 226
Beijing 213
Houston 189
Jacksonville 176
Seattle 167
Wilmington 155
Cambridge 152
Princeton 145
Lauterbourg 119
New York 117
Los Angeles 103
Istanbul 97
Ho Chi Minh City 96
Helsinki 84
Dublin 78
Dallas 75
Chandler 72
Hanoi 72
Ann Arbor 70
Council Bluffs 62
São Paulo 60
Munich 53
Warsaw 52
Moscow 48
Buffalo 45
Chicago 45
Brescia 44
Redondo Beach 40
San Diego 39
Milan 36
Des Moines 33
Shanghai 33
Frankfurt am Main 31
Nuremberg 29
Santa Clara 27
London 26
Orem 23
Chennai 22
Tokyo 22
Toronto 22
Turku 21
Romola 20
San Francisco 19
Rio de Janeiro 17
Denver 16
Meram 16
Montreal 16
Florence 15
Rome 14
Brno 13
Düsseldorf 13
Tianjin 13
Algiers 12
Atlanta 12
Belo Horizonte 12
Brasília 12
Brooklyn 12
Dhaka 12
Mexico City 12
Baghdad 11
Curitiba 11
Haiphong 11
Kocaeli 11
Brussels 10
Changsha 10
Jinan 10
Stockholm 10
Amsterdam 9
Boston 9
Campinas 9
Phoenix 9
Quito 9
Vienna 9
Buenos Aires 8
Goiânia 8
Jeddah 8
Johannesburg 8
Nanjing 8
Tashkent 8
Bologna 7
Cape Town 7
Da Nang 7
Hortolândia 7
Manchester 7
Ninh Bình 7
Shenyang 7
Sorocaba 7
Ardabil 6
Augusta 6
Bogotá 6
Cairo 6
City of London 6
Falkenstein 6
Gonars 6
Totale 6.159
Salva come PNG Salva come JPEG
Nome #
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis 171
A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection 165
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): A phase III, randomized, multicentre trial of the italian oncology group for clinical research (GOIRC) 156
Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN 151
Genetics of ANCA-Associated Vasculitis 149
SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response 134
Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy 132
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia 129
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience 128
A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis 124
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 124
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 122
Nonlupus Full House Nephropathy 121
Pneumocystis Jirevocii and SARS-CoV-2 co-infection: A common feature in transplant recipients? 118
[Glomerulonefriti da tossici e farmaci] 118
Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features 116
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 116
[Infection-related glomerulonephritis: the new face of an old disease] 115
Fcγ-receptor 3B (FCGR3B) copy number variations in patients with eosinophilic granulomatosis with polyangiitis 113
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 110
Chronic periaortitis with thoracic aorta and epiaortic artery involvement: A systemic large vessel vasculitis? 104
[Peritoneal dialysis: what have we learned from the Covid-19 pandemic?] 103
Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series 102
Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial 102
Impact of rituximab trials on the treatment of ANCA-associated vasculitis 102
PTPN22 R620W polymorphism in the ANCA-associated vasculitides 102
[The complex etiopathogenesis of focal segmental glomerulosclerosis] 102
Impact of COVID-19 vaccines in patients on hemodialysis: an Italian multicentre cohort study 102
[Managing patients in dialysis and with kidney transplant infected with Covid-19] 101
Update on ANCA-associated vasculitis: from biomarkers to therapy 101
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC) 99
Lupus nephritis and B-cell targeting therapy 98
The role of analytical methods for the determination of trace elements in environmental biomonitors 98
Measurement of damage in systemic vasculitis: A comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index 98
[ADPKD and intracranial aneurysms: indications for screening, follow-up and clinical management] 98
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis 97
Orofacial granulomatosis treated with low-level laser therapy: A case report 97
IgG4 immune response in Churg-Strauss syndrome 97
Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-α in patients with renal cell carcinoma 96
Avacopan for the treatment of ANCA-associated vasculitis 96
An Initial Low-Dose Etelcalcetide Dosing Strategy in Hemodialysis Patients With Moderate Secondary Hyperparathyroidism is Effective and Cost-Saving 95
Magnetic resonance imaging in central nervous system vasculitis in a patient affected by crioglobulin-negative hepatitis C virus infection: A likely correlation 95
Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis 95
Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease 95
Monoallelic pathogenic IFT140 variants are a common cause of autosomal dominant polycystic kidney disease–spectrum phenotype 94
Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis 94
Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer? 93
Peripheral inflammatory arthritis in patients with chronic periaortitis: Report of five cases and review of the literature 92
FCGR2A single nucleotide polymorphism confers susceptibility to childhood-onset idiopathic nephrotic syndrome 91
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial 91
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients 88
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. 87
Lessons From the Clinic: ADPKD Genetic Test Unraveling Severe Phenotype, Intrafamilial Variability, and New, Rare Causing Genotype 87
The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult 86
Genetics of ANCA-associated vasculitides: HLA and beyond 86
Hemodialysis techniques and outcomes in patients with COVID-19: The Brescia experience 85
Chronic periaortitis associated with membranous nephropathy: Clues to common pathogenetic mechanisms 85
Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis 85
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) 85
Expanding the variability of the ADPKD-GANAB clinical phenotype in a family of Italian ancestry 84
Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD 82
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial 81
Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination 80
The Authors Reply 79
[State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy] 79
Association of a polymorphism of the Fc gamma-receptor 2A (FCGR2A) gene with chronic periaortitis 78
FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis 78
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 76
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort' 76
Sustained post-rituximab B cell depletion is common in ANCA-associated Vasculitis and affected by sex and renal function 72
[Anti-SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases. Recommendations of the Italian Society on Nephrology's Working Group on Renal Immunopathology (Vaccine Task Force)] 72
Feasibility of MALDI-MSI-Based Proteomics Using Bouin-Fixed Pathology Samples: Untapping the Goldmine of Nephropathology Archives 71
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies 70
Variable Expressivity of HNF1B Nephropathy From Renal Cysts and Diabetes to Medullary Sponge Kidney Through Tubulo-interstitial Kidney Disease 69
Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study 67
Clinical Significance of the Cystic Phenotype in Alport Syndrome 67
Congo Red Staining in Digital Pathology: The Streamlined Pipeline for Amyloid Detection Through Congo Red Fluorescence Digital Analysis 66
Changes in 24-hour blood pressure profile after 12 weeks of dapagliflozin treatment in patients with diabetic kidney disease: An Italian multicenter prospective study 66
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? 66
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab 66
The safety of corticosteroid therapy in IGA nephropathy: analysis of a real-life Italian cohort 65
Rituximab in Membranous Nephropathy 65
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy 65
Treatment goals in ANCA-associated vasculitis: defining success in a new era 64
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial 63
Galileo—an Artificial Intelligence tool for evaluating pre-implantation kidney biopsies 63
Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy 63
Peritoneal dialysis discontinuation: to the root of the problem 63
Editorial: “Toward Precision Medicine in Vasculitis” 63
The ideal marker for measuring GFR: what are we looking for? 62
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial 62
Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia 62
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 61
Occupational Exposures and Smoking in Eosinophilic Granulomatosis With Polyangiitis: A Case–Control Study 60
Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study 59
Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey 58
Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome 57
Treatment of secondary hyperparathyroidism in hemodialysis patients: a comparison between two Italian centers to evaluate real-world guideline implementation 56
COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases 56
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis 55
Totale 9.083
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.466
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.466
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021389 0 0 0 0 0 0 0 0 0 165 114 110
2021/2022600 44 104 22 18 2 64 28 36 37 58 37 150
2022/2023373 83 2 7 7 20 114 0 30 48 2 28 32
2023/2024811 32 30 29 63 53 111 28 34 236 11 26 158
2024/20251.998 8 26 42 236 150 153 199 85 209 277 397 216
2025/20264.265 338 603 412 743 387 273 599 213 306 391 0 0
Totale 10.241